Bausch Health’s DEXAVEN (Dexamethasone Phosphate) Receives New Sign In Poland To Deal with Clients With SARS-CoV-2 (COVID-19)

LAVAL, QC, Dec. 30, 2020 /PRNewswire/ — Bausch Overall health Businesses Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that the Business for Registration of Medicinal Products and solutions, Professional medical Devices and Biocidal Products in Poland has granted an further new indicator for DEXAVEN (dexamethasone phosphate) alternative for injection, 4 mg/ml, for the treatment of COVID-19 in grownup and adolescent individuals (12 years of age and older weighing at least 40 kg) who demand oxygen remedy. DEXAVEN is a corticosteroid that lessens irritation.

“We’re delighted that Poland’s Office for Registration of Medicinal Goods, Clinical Equipment and Biocidal Goods has permitted DEXAVEN for the treatment of indicators thanks to COVID-19, mainly because now sufferers in Poland have a further treatment selection to battle this virus,” claimed Thomas J. Appio, president, Bausch + Lomb/Intercontinental, Bausch Overall health. “Bausch Health continues to assess our wellness care solutions and medications around the planet to identify if they may well present important therapy alternatives for COVID-19, and we will carry on to do what we can to help in the world wide attempts to stop the pandemic.”

Dexamethasone-containing products in the United States are not authorized as a procedure for COVID-19 by the U.S. Meals and Drug Administration. Patients really should only use these solutions in accordance with their accredited label and the directions of their physician.

About Bausch Well being

Bausch Health Corporations Inc. (NYSE/TSX: BHC) is a world-wide enterprise whose mission is to increase people’s lives with our health and fitness care solutions. We establish, manufacture and market a range of pharmaceutical, medical device and over-the-counter merchandise, generally in the therapeutic locations of eye health, gastroenterology and dermatology. We are providing on our commitments as we develop an innovative organization devoted to advancing world wide health and fitness. More details can be identified at www.bauschhealth.com.

Forward-on the lookout Statements

This information release may include ahead-seeking statements, which might commonly be discovered by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variants or related expressions. These statements are centered on the existing expectations and beliefs of management and are matter to specific dangers and uncertainties that could trigger precise effects to vary materially from those people described in the ahead-searching statements. These hazards and uncertainties contain, but are not minimal to, the dangers and uncertainties talked about in the Bausch Health’s most latest yearly report on Kind 10-K and in depth from time to time in Bausch Health’s other filings with the U.S. Securities and Trade Fee and the Canadian Securities Administrators, which things are incorporated herein by reference. They also involve, but are not limited to, hazards and uncertainties brought on by or relating to the evolving COVID-19 pandemic, and the dread of that pandemic and its potential consequences, the severity, duration and future impression of which are remarkably uncertain and are unable to be predicted, and which might have a material adverse effect on Bausch Overall health, which includes but not minimal to its project enhancement timelines, and prices (which might maximize). Viewers are cautioned not to spot undue reliance on any of these ahead-hunting statements. These forward-on the lookout statements speak only as of the day hereof. Bausch Health undertakes no obligation to update any of these ahead-wanting statements to reflect functions or circumstances after the date of this news launch or to replicate real results, unless demanded by law.

Watch primary material to down load multimedia: http://www.prnewswire.com/information-releases/bausch-healths-dexaven-dexamethasone-phosphate-receives-new-indication-in-poland-to-handle-people-with-sars-cov-2-covid-19-301199175.html

Supply Bausch Health and fitness Organizations Inc.